Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2021

View Archived Issues

HepaRegeniX initiates first-in-human trial of HRX-0215

China Pharmaceutical University targets WDR5/MLL1 interaction with DDO-2213

GentiBio closes Series A financing to advance its pipeline of engineered Treg therapies

First patient dosed in phase I study of AVA-6000

IN8bio completes dosing of first cohort in phase I study of INB-100

Janssen describes mutant FimH compositions

Positive interim analysis data from phase II/III study of plonmarlimab in severe COVID-19

Jiangsu Hengrui Medicine and collaborators patent antibacterials

New PTPN11 inhibitors discovered at Betta Pharmaceuticals

Nuvation Bio identifies new adenosine A2a receptor antagonists

SAB-185 potently neutralizes delta and lambda SARS-CoV-2 variants in nonclinical studies

Oxford Vacmedix receives approval for its first-in-human study of OVM-200 cancer vaccine

Lynk initiates dosing in phase I study of its triple-kinase inhibitor LNK-01002

RemeGen completes phase II study of telitacicept in IgAN

FDA clears IND for XeriSol levothyroxine subcutaneous injection

Imatinib preserves Beta-cell function in subjects with type 1 diabetes

Cali Biosciences initiates MERIT-1 study of long-acting ropivacaine for postoperative pain

Further data from phase I study of UV-1 in metastatic melanoma

JadiCell shows superior neurogenesis induction in model of viral-induced cognitive dysfunction

Algernon Pharmaceuticals announces SCLC research program for ifenprodil

Enrollment ongoing in phase II studies of ABBV-154

Marker of neuroaxonal injury is also a marker of worse outcomes in COVID-19 patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...